NewAmsterdam Pharma
NAMS
18.41
-1.10
-5.64%
NewAmsterdam Pharma
US · NAMS
#2583 by market cap
Listed 1970
18.41
-1.10
-5.64%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About NewAmsterdam Pharma
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
- Founded
- 2022
- CEO
- Dr. Michael Harvey Davidson, M.D.
- Employees
- 100
- Headquarters
- Naarden, Noord-Holland, Netherlands (the)
- Fiscal year end
- 12-31
- Website
- newamsterdampharma.com
Company profile
- Exchange
- US
- Symbol
- NAMS
- Market-cap rank
- #2583
- Listing date
- 1970-01-01
- Market cap
- 2.21B
- Float cap
- 1.51B
- Shares out
- 119.93M
- Float shares
- 81.84M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
NewAmsterdam Pharma discussion 0 comments